Recombinant CLDN18.2 (Zolbetuximab Biosimilar) 抗体
适用: 人
FACS, BLI, ELISA, Func, SPR
宿主: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原 See all CLDN18.2 (Zolbetuximab Biosimilar) products
- CLDN18.2 (Zolbetuximab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Human
- Expression System
- CHO Cells
-
克隆类型
- 单克隆
-
标记
- This CLDN18.2 (Zolbetuximab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
- 原理
- Anti-CLDN18.2 Reference Antibody (zolbetuximab)
- 序列
- QVQLQQPGAE LVRPGASVKL SCKASGYTFT SYWINWVKQR PGQGLEWIGN IYPSDSYTNY NQKFKDKATL TVDKSSSTAY MQLSSPTSED SAVYYCTRSW RGNSFDYWGQ GTTLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK,DIVMTQSPSS LTVTAGEKVT MSCKSSQSLL NSGNQKNYLT WYQQKPGQPP KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCQNDYSY PFTFGSGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
- 产品特性
- Anti-CLDN18.2 Reference Antibody (zolbetuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
- 纯度
- >95 %
- 亚型
- IgG1
-
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 说明
-
Therapeutic Agents by Target and Mechanism: CLDN18.2 inhibitors, ADCC, complement-dependent cytotoxicity
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 浓度
- 1 mg/mL
- 缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- 储存条件
- 4 °C,-80 °C
- 储存方法
- +4°C,-80°C
-
- 抗原
- CLDN18.2 (Zolbetuximab Biosimilar)
- Abstract
- CLDN18.2 (Zolbetuximab Biosimilar) 产品
- 物质类
- Biosimilar
- 分子量
- 145.5 kDa
- UniProt
- P56856
-
You are here:
